Views & Analysis Janssen: ‘Open dialogue’ needed with HTAs to improve access The world of life sciences is changing rapidly, and the traditional ways of assessing drugs may no longer be fit for purpose.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends